Page 2 - Monopar Therapeutics Inc Stock Exchange News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Monopar therapeutics inc stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Monopar Therapeutics Inc Stock Exchange Today - Breaking & Trending Today

Monopar Announces New Drug Candidate, MNPR-202, and

Development of novel Camsirubicin analog expands Monopar’s therapeutic pipeline. ....

United States , United Kingdom , National University Of Singapore , Singapore General , Chandler Robinson , Anand Jeyasekharan , Kimr Tsuchimoto , Andrew Mazar , Monopar Therapeutics Inc , Cancer Institute Of Singapore , Research Centres Of Excellence , Exchange Commission , Cancer Science Institute Of Singapore , National Research Foundation , Therapeutics Inc , Ministry Of Education , Cancer Science Institute , National University , Chief Scientific Officer , Principal Investigator , Cancer Institute , Research Centres , Private Securities Litigation Reform Act , Nasdaq Mnpr , Monopar Therapeutics Inc , ஒன்றுபட்டது மாநிலங்களில் ,

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer

Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
February 11, 2021 07:30 ET
| Source:
Monopar Therapeutics Inc.
Monopar Therapeutics Inc.
Wilmette, Illinois, UNITED STATES
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the publication of a peer-reviewed study in the
European Journal of Cancer which shows the potential utility of MNPR-101 as a uPAR imaging agent to improve surgical outcomes in bladder cancer.
Using Monopar’s proprietary humanized uPAR antibody, MNPR-101, a multimodal imaging probe was developed and tested ....

Kimr Tsuchimoto , Andrew Mazar , Exchange Commission , Leiden University Medical Center , Monopar Therapeutics Inc , European Journal , Chief Scientific Officer , Cornelis Sier , Image Guided Surgery , Private Securities Litigation Reform Act , Therapeutics Inc , Nasdaq Mnpr , Mnpr 101 , ஆண்ட்ரூ மசார் , பரிமாற்றம் தரகு , ஐரோப்பிய இதழ் , தலைமை அறிவியல் அதிகாரி , படம் வழிகாட்டப்பட்டது அறுவை சிகிச்சை , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , சிகிச்சை இன்க் ,